Zynerba (ZYNE) supplier map: what the vendor roster reveals to investors

Zynerba Pharmaceuticals operates as a clinical-stage specialty pharmaceutical company that funds development and corporate operations primarily through capital markets activity while outsourcing investor relations, proxy solicitation, and transfer-agent functions to third-party vendors. The company monetizes future value through its pipeline and today’s investor financing; its supplier relationships are concentrated in capital markets services and shareholder administration, which directly support liquidity and governance rather than product manufacturing.

If you want a quick supplier-risk snapshot tied to capital markets exposure, start here: https://nullexposure.com/

Why supplier relationships matter for an equity-financed biotech

Zynerba’s vendor list is not a roster of contract manufacturers or CROs — it is a set of capital markets and investor-services partners that influence fundraising velocity, investor communications, and shareholder voting mechanics. For active investors and operators, that translates into clear, actionable signals about contracting posture, dependency, and governance support:

Contracting posture: Zynerba contracts external sales agents and investor-relations firms for discrete engagements such as Controlled Equity Offering sales agreements and annual meeting support. These are transactional, market-facing vendor relationships rather than long-term supply contracts.
Concentration: The supplier set shows diversified capital markets coverage across boutique and bulge‑bracket firms, reducing single-provider concentration for fundraising execution.
Criticality: These vendors are operationally critical to fundraising and shareholder management: sales agents affect capital access and transfer agents plus proxy firms affect record-keeping and vote outcomes.
Maturity: Relationships stretch over multiple years (2019 sales-agreement event and 2023 shareholder-service engagements), which indicates recurring use of external capital‑markets services rather than one-off ad hoc hires.

The full supplier list (what each relationship contributes)

Below are the relationships extracted from public filings and press notices. Each entry includes a concise plain‑English description and the cited source.

Cantor Fitzgerald & Co.
Cantor Fitzgerald served as one of the sales agents under Zynerba’s Controlled Equity Offering SM Sales Agreement executed in August 2019, a contract used to facilitate at‑the‑market equity issuances. According to a CityBiz summary of Zynerba’s FY2021 results, Cantor Fitzgerald was named alongside other firms in that 2019 sales agreement (CityBiz, coverage of FY2021 results; 2019 sales-agreement reference: https://www.citybiz.co/article/60270/zynerba-pharmaceuticals-reports-first-quarter-2021-financial-results-and-operational-highlights/).
Canaccord Genuity, LLC
Canaccord Genuity was listed as a co‑agent on the same August 2019 Controlled Equity Offering sales agreement, providing execution capacity for at‑the‑market equity placements. This role is documented in Zynerba’s public statements captured in the CityBiz FY2021 article (CityBiz, FY2021 coverage; link above).
H.C. Wainwright & Co. LLC
H.C. Wainwright functioned as a sales agent under Zynerba’s 2019 sales agreement, supporting securities distribution for equity financing activities described in Zynerba’s FY2021 communications. The CityBiz report records H.C. Wainwright as part of that syndicate (CityBiz, FY2021 coverage; link above).
Ladenburg Thalmann & Co. Inc.
Ladenburg Thalmann is included among the 2019 sales agents named by Zynerba for Controlled Equity Offering activity, indicating the company’s strategy of engaging multiple broker‑dealers to execute equity placements (CityBiz FY2021 report; link above).
MacKenzie Partners, Inc.
MacKenzie Partners was retained as proxy solicitor for Zynerba’s annual meeting processes; investors seeking assistance with voting were directed to contact MacKenzie by email or phone per the company’s shareholder notice. This engagement is described in Zynerba’s reconvened annual meeting announcement on August 8, 2023 (InvestorUprising / PR News distribution; 2023-08-08: https://markets.financialcontent.com/prnews.investoruprising/article/gnwcq-2023-8-8-zynerba-pharmaceuticals-announces-new-date-for-reconvened-annual-meeting).
ICR Westwicke
ICR Westwicke is listed as an investor relations contact for Zynerba, indicating an outsourced IR function to handle media and analyst relations. The company’s August 2023 meeting notice references Zynerba contacts at ICR Westwicke (InvestorUprising / PR News, 2023 filing; link above).
American Stock Transfer & Trust Company, LLC (AST)
AST acted as Zynerba’s transfer agent for proxy mailings and vote processing, with shareholders instructed to return proxy cards to AST in postage‑paid envelopes. This transfer‑agent role is cited in Zynerba’s reconvened annual meeting announcement (InvestorUprising / PR News, 2023-08-08; link above).

What this vendor mix means for investors and operators

Capital markets readiness: Engaging four different broker‑dealers for the 2019 Controlled Equity Offering signals Zynerba’s intent to maintain multiple execution channels for equity raises. That structure supports flexibility in market access and pricing execution.
Governance hygiene: The use of established proxy solicitors, an institutional transfer agent, and a professional IR firm signals that Zynerba runs standard governance and shareholder‑communications processes consistent with public‑company norms.
Operational risk vector: These vendors are critical to funding and corporate governance. Disruption to sales-agent capabilities would constrain near‑term capital access; disruptions to AST or MacKenzie would impact voting and shareholder servicing.
Vendor concentration is low across categories: Sales‑agent services are split among several firms while governance/IR functions rely on single providers, which creates low concentration for fundraising execution and single points of failure for shareholder services.

Explore a supplier-focused risk scorecard and deeper vendor histories at https://nullexposure.com/ — the quickest route to convert supplier intelligence into investment signals.

Practical implications for portfolio managers

Prioritize monitoring of: (1) any new equity‑offering notices that would re‑activate or expand these sales‑agent agreements, and (2) proxy‑solicitor or transfer‑agent changes ahead of annual meetings.
Integrate vendor notices and 8‑K filings into liquidity stress tests because these providers directly affect Zynerba’s ability to raise capital and administer shareholder action.

Final takeaways and next steps

Zynerba’s supplier roster is narrowly focused on capital‑markets execution and shareholder services — not on drug development vendors — which requires investors to evaluate funding pathways and governance continuity rather than manufacturing supply chains. The vendor mix provides both redundancy for fundraising execution and concentrated dependence for shareholder administration.

For a systematic supplier risk assessment and up‑to‑date relationship mapping, visit https://nullexposure.com/ and convert vendor signals into actionable portfolio decisions.

If you want a tailored report on Zynerba’s vendor exposure or comparable profiles across the specialty‑pharma sector, start at https://nullexposure.com/ — our platform maps supplier roles to investor risk metrics and governance indicators.